MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Dividend History

MoonLake Immunotherapeutics is a biotechnology company focused on developing innovative immuno-oncology therapies. The company specializes in creating treatments that harness the body's immune system to target and combat cancer, with an emphasis on complement pathway modulation. Its pipeline includes a variety of investigational drugs aimed at improving outcomes for patients with difficult-to-treat cancers.

Dorfstrasse 29, Zug, V8, 6300
Phone: 41 41 510 8022
Website: https://www.moonlaketx.com

Dividend History

MoonLake Immunotherapeutics Class A Ordinary Shares currently does not pay dividends

Company News

Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight

The psoriasis pipeline has several drugs in mid- and late-stage development, including Imsidolimab, TAK-279, and Sonelokimab, which are expected to positively impact the market. The treatment landscape is expanding with new therapies from various companies.

GlobeNewswire Inc.

Featured Companies: ANAB
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

MoonLake Immunotherapeutics secures up to $500 million in non-dilutive financing from Hercules Capital, strengthening its financial position to advance its lead candidate sonelokimab. The company plans to provide clinical updates, including on its Phase 3 trials in hidradenitis suppurativa and Phase 2 trial in palmoplantar pustulosis.

GlobeNewswire Inc.

Featured Companies: HTGC
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

MoonLake Immunotherapeutics has initiated three new clinical trials for its Nanobody® sonelokimab in adolescent hidradenitis suppurativa, palmoplantar pustulosis, and axial spondyloarthritis, expanding its pipeline across dermatology and rheumatology indications.

GlobeNewswire Inc.
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, will host a Capital Markets Update on September 11, 2024, providing business updates, pipeline updates, and details on the Phase 3 programs for its investigational Nanobody® sonelokimab in hidradenitis suppurativa and psoriatic arthritis.

GlobeNewswire Inc.
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire Inc.

Dividend data last updated 06/06/2025 23:47:08 UTC